Mayne Pharma Launches Fabior®And Sorilux® in the United States

Mayne Pharma has announced the launch of Fabior® (tazarotene) Foam, 0.1% and Sorilux® (calcipotriene) Foam, 0.005% in the United States by Mayne Pharma’s Specialty Brands division.

These foam products, previously marketed by GlaxoSmithKline (GSK), were acquired by Mayne Pharma in August 2016 and are complementary dermatology products to Doryx®, the first branded product launched by Mayne Pharma’s Specialty Brands division in the United States in May 2015.

Fabior is a patent-protected foam product indicated for the topical treatment of acne, the most prevalent skin disease in the United States affecting as many as 50 million people of all ages*. Fabior is part of the single active retinoid market in which 5 million prescriptions are written annually. This market is significantly larger than the oral antibiotic acne market that Doryx participates in as topical products are used more frequently by acne patients across the disease spectrum ranging from mild and moderate to severe acne cases.

Sorilux is a patent-protected foam product indicated for the topical treatment of plaque psoriasis of the scalp and body affecting up to 6 million Americans each year^*. Sorilux is part of the single active Vitamin D market in which 0.5 million prescriptions are written annually.

Mayne Pharma’s CEO Scott Richards said, “Both Fabior and Sorilux are a great strategic fit with the existing Doryx franchise and participate in attractive and growing markets. Both products are well differentiated with compelling clinical data that physicians and patients will appreciate.  The foam delivery platform has a well-established reputation with dermatologists due to ease of application, especially in hair-bearing areas and under clothing. With a focused and sustained marketing effort, we can further support the needs of patients and dermatologists and these products will become important treatment options for people with acne and plaque psoriasis.

“We have met our planned commercial launch timing and have also now internalized our 60-person dermatology sales team from a third-party contract sales organization, which is expected to provide cost savings, improved ability to attract and retain talent, improved performance management and, ultimately, improved sales force effectiveness. Over time, we expect to commercialize complementary product innovations in dermatology and other specialty therapeutic areas utilizing the company’s internal pipeline or via targeted in-licensing and/or product acquisitions.”